CureVac
179 articles about CureVac
-
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
2/10/2023
CureVac N.V. announced the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by CureVac.
-
CureVac Announces Proposed Public Offering of Common Shares - February 07, 2023
2/7/2023
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that it intends to offer $200 million of its common shares in an underwritten public offering.
-
CureVac Welcomes Myriam Mendila as New Chief Development Officer
2/1/2023
CureVac N.V. today announced that Myriam Mendila has taken up her role as CureVac's Chief Development Officer, as previously announced.
-
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
1/31/2023
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced its inclusion in the second annual "Innovation Momentum: The Global Top 100" report by LexisNexis®.
-
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
12/14/2022
CureVac N.V. announced that Chief Executive Officer Franz-Werner Haas, Chief Financial Officer Pierre Kemula and Interim Chief Development Officer Ulrike Gnad-Vogt sold an aggregate of 103,775 CureVac common shares.
-
August 1 is RNA Day. BioSpace takes a look at recent breakthroughs in RNA therapeutics, and the vast potential of the "vital biological molecule."
-
“The applications for mRNA are quite broad, because, basically, you are giving information to a cell to make any protein you want," CureVac CFO Pierre Kemula told BioSpace.
-
Pfizer and BioNTech initiated a Phase II trial of an enhanced COVID-19 vaccine while fending off lawsuits against CureVac and Alnylam over their technology.
-
Battle of the Patents: Daiichi Sankyo, Seagen, Alnylam, CureVac, Pfizer, BioNTech & Moderna
7/20/2022
The LPN technology used in the mRNA COVID-19 vaccines has been the target of numerous patent challenges. Here's a look at recent biopharma patent disputes. -
Moderna has dosed its first participant in a Phase I clinical trial of mRNA-1215, a vaccine designed to fight the Nipah virus (NiV), a virus contracted in humans through animals.
-
CureVac has filed a lawsuit against BioNTech and two of its subsidiaries for allegedly infringing on its intellectual property rights over mRNA technology used in the COVID-19 vaccine.
-
Even though the COVID-19 pandemic appears to be under control, it's clear that it's not over, with the rise of more subvariants. Read on for more details.
-
CureVac Announces Voting Results of General Meeting - June 22, 2022
6/22/2022
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the voting results of the Company's annual general meeting.
-
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
6/8/2022
CureVac N.V. announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.
-
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
6/8/2022
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022.
-
Germany’s CureVac is partnering with Belgium’s myNEO to identify specific cancer antigens in order to develop novel mRNA immunotherapies for cancer vaccines.
-
GlaxoSmithKline exceeded expectations for its first-quarter sales and earnings forecasts. This was largely driven by its sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and its Shingrix vaccine against shingles.
-
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
4/11/2022
CureVac N.V. and GSK today announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany.
-
The FDA is looking at revising the current vaccine strategy and emphasizing that individuals need to consider their own risk tolerance. For that and more, continue reading.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.